TABLE 2.

Average Total Blood Loss (mL), Average Number of Gauze Applications, Overall Survival Completed Through the 180-Minute Observation Period, and Positive Angiographic Perfusion Demonstrated for Each Hemostatic Agent Compared With Control Agent, CG

Hemostatic Agent	CG (Control)	BL-IX	TAC	CS	CR	EP	XR	XS	p
Average blood loss, mL	260 ± 319	913 ± 515	135 ± 127	112 ± 115	545 ± 734	297 ± 662	554 ± 613	778 ± 660	0.02
No. gauze applications	1.6	2.6	1.4	1.6	2	2.1	1.9	2.4	0.03
Overall survival, %	86	29	71	100	86	71	71	100	0.02
Angiographic perfusion, %	62	50	20	43	60	100	100	43	0.09

CS, ChitoSAM 100; EP, EVARREST Fibrin Sealant Patch; TAC, TAC Wrapping Gauze; XR, ChitoGauze XR Pro.